J&C Sciences

J&C Sciences is a South Korean private drug discovery venture focused on small-molecule therapeutics for oncology and antiviral diseases. The company highlights medicinal chemistry capabilities in nucleosides, phosphonate nucleosides, prodrug design, chemical process development, impurity profiling, scale-up, and sample preparation, and it also appears to perform CRO-style chemistry services. Its lead disclosed program is JNC-1043, a first-in-class importin beta inhibitor being developed primarily for triple-negative breast cancer and other hard-to-treat cancers, with preclinical data presented in academic conference settings and patent filings/publications supporting the asset. Public materials also indicate interest in antiviral programs, including COVID-19-related research, though named clinical assets beyond JNC-1043 are not clearly disclosed. Overall, J&C Sciences appears to be an early-stage medicinal-chemistry-driven biotech centered on proprietary small molecules plus chemistry/process-development services.